Download Free Medical Practical Psychopharmacology in Children and Adolescents PowerPoint Presentation

Practical Psychopharmacology in Children and Adolescents PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : Check out this medical presentation on Neurology, which is titled "Practical Psychopharmacology in Children and Adolescents", to know about Pharmacokinetics in Children, ADHD Medications, Antidepressants and the Black Box, and Anxiety Disorders.

Tags : Neurology, Practical Psychopharmacology, Children, Adolescents, Pharmacokinetics, ADHD Medications, Antidepressants, Anxiety Disorders

Published on : Aug 23, 2021 | Views : 1632 | Downloads : 5

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Practical Psychopharmacology in Children and Adolescents Anoop Vermani MD Fellow, Child and Adolescent Psychiatry
Slide 2-

Basic points we’ll cover today: Pharmacokinetics in Children ADHD Medications Antidepressants and the Black Box Anxiety Disorders Other Topics Questions
Slide 3-

Take Home Points 80% of Rx are not approved by the FDA for use in children 1 Fewer evidence-based studies in children than adult psychiatry Often have to use your best judgment based on adult literature and clinical experience 1 Pharmacotherapy plus psychotherapy tends to have better results than pharmacotherapy alone 2,3 Strong stigma against using medications in treating pediatric mental illness
Slide 4-

Pharmacokinetics in Pediatrics Lipophilic Medications: Most psychotropic medications are highly lipophilic The percentage of total body fat increases during the first year of life, then decreases gradually until puberty 4 Children have different volumes of fat for drug storage at different ages. CYP/Metabolizing enzymes: Both CYP450 and phase II drug metabolizing enzymes generally are absent in infancy, though rapidly develop over the first few years of life. Toddlers and older children may have levels of these drug-metabolizing enzymes which exceed adult levels! These decline until puberty, where they generally remain the same until adulthood.
Slide 5-

Pharmacokinetics in Pediatrics Liver mass effects: Relative to body weight, the liver mass of a toddler is 40-50% greater than an adult. A 6 year old is 30% greater than an adult. Children tend to clear drugs more rapidly than adults Children may require higher mg/kg concentrations to achieve the same plasma levels. Renal filtration: By age 1, GFR and renal tubular mechanisms for secretion have reached adult levels However, fluid intake may be greater in children relative to adults Therefore, medications have a more rapid renal clearance in children compared to adults
Slide 6-

Stimulants and ADHD Affects 5-10% of children in the US 5 7 Million Ambulatory visits in 2006 >$31.1 Billion annual US cost 2:1 Male:Female ratio in general population but up to 9:1 in mental health clinics 6 50% of clinical samples have ODD or CD 6 25-30% have comorbid anxiety disorders 6 20-25% have comorbid learning disorders 6 Why do we care?
Slide 7-

ADHD Medications Can help greatly with quality of life by affecting the ability to focus, decrease physical hyperactivity Combination of medications and behavioral interventions have been shown as a superior treatment to either alone 7 The goal of medication is symptom reduction, which requires careful assessment and ongoing monitoring of mental status/psychosocial functioning Use of Subscales can be helpful (Vanderbilt, Connors, etc) but not diagnostic – clinical judgment remains most important Stimulants Most widely used 65-75% efficacy in treating ADHD symptoms vs 4-30% placebo response Only 55% of patients with ADHD get medication treatment Non-stimulants May have fewer (or different) side effects Typically considered second line treatment
Slide 8-

The Stimulants Methylphenidate vs. Amphetamine Methylphenidate blocks the reuptake of DA and NE but has little effect on presynaptic release of dopamine 8 Amp blocks reuptake of DA and NE and increases release of DA and NE 8 Long Acting Forms - 3 delivery options: SODAS/DIFFUCAPS: combination of immediate and extended release beads OROS: capsule with H2O permeable holes which release medication depending on osmotic pressure 3rd option: Lisdexamfetamine, a prodrug bound to L-lysine which uses GI tract to metabolize  dextroamphetamine
Slide 9-

Practical Steps in Stimulant Treatment Refer to handouts for dosing information Can titrate with short acting as needed on top of long acting Base your clinical decisions on the best interests of the child Adverse effects: Common (10-50%): nausea, stomach upset, decreased appetite, insomnia, headache Uncommon: motor tics (9%), dysphoria, irritability, hallucinations, “zombie” Cardiac: 25 cases of sudden death; risk is 0.7-1.5/100K children <16 Growth: MTA – 1cm/year decrease in height over 1-3 yrs. of continuous treatment, but other studies show no difference
Slide 10-

ppt slide no 10 content not found
Slide 11-

Non-Stimulant Treatment of ADHD Atomoxetine: Selective NE reuptake inhibitor Advantages: low abuse potential, less insomnia/growth problems Disadvantages: delayed onset of effect (2-4 wks), lower efficacy than stimulants Dose based on weight: 0.5mg/kg/day, up to 1.2mg/kg/day as tolerated Adverse effects: nausea, stomach pain, moodiness, increased heart rate, Black Box – suicidality
Slide 12-

Other Non-stimulant Meds for ADHD Buproprion: NE reuptake and DA reuptake inhibitor Dosing is somewhat unclear in children; adults = mean 393mg/day of Wellbutrin XR a2 Adrenergic Agonists: May strengthen working memory by improving functional connectivity in prefrontal cortex Clonidine: less effective than stimulants, used as adjunct to manage tics, sleep problems and aggression Adverse Effects include bradycardia and sedation Guanfacine: more selective for a2a receptor less sedation/dizziness than clonidine 2-4 mg with effect between 2-4 weeks
Slide 13-

Major Studies in ADHD Tx MTA study 7 14 month RCT with 579 children Behavioral modification + medication > meds alone > BM alone > community care PATS study 13 303 Preschool children (3 – 5½) Lower efficacy than older children (MTA) but still better than placebo More adverse effects than seen with MTA
Slide 14-

Mood Disorders in Children Major Depressive Disorder Criteria are same for children, but clinically children often appear irritable 1 in 20 teens suffer from depression 9 Of these, only 1/3 receive treatment of any kind Depression is a chronic illness Can use screening tools (PHQ-9, Columbia Dep. Scale), but gold standard is clinical examination Frequent monitoring, psycho-education, social support, and psychotherapy (CBT, IPT, supportive Tx) is standard of care 9
Slide 15-

Suicidality in Children/Adolescents Suicide is the 3rd leading cause of death in children ages 10-19 10 90% of suicides in youth are associated with psychiatric illness 10 Only 2% of youths who have committed suicide are actually taking any kind of psychiatric medications 10 Most of these children who committed suicide sought out treatment only 1 month prior to the event 10 35-50% of depressed children receiving care have made or will make a suicide attempt 10 2-8% completing within a 10 year period in adults In 2003, early warnings from the UK appeared “3.2% risk of self-harm and potentially suicidal behavior in paroxetine-treated patients vs. 1.5% in placebo” Warnings expanded over the next year, encompassing more antidepressants, until…
Slide 16-

The Black Box Warning October 2004: Black Box warning for suicidality in adolescents and children 24 Trials examined, containing 4400 children and adolescents 9 Antidepressants included No completed suicides in these trials More youth on a med spontaneously reported suicidality vs. youth on placebo (4/100 vs. 2/100) 11 This included suicidal thoughts and behaviors but again, none of these studies had any completed suicides. 11 A more recent trial has shown that a decrease in the amount of SSRI use has led to an increase in the suicide rates in children and adolescents. 10
Slide 17-

Suicide Prevention in Depressed Children and Adolescents Encourage home safety Adolescents are much more likely to kill themselves with firearms 12 Children are much more likely to kill themselves by strangulation 12 Ask about suicide and watch for suicidal behavior Monitor and ask about drug/alcohol use Monitoring after starting antidepressant: Weeks 1-4: weekly Weeks 5-12: every other week After Week 12: as clinically indicated (Q4wks?) Bottom line is any child on an SSRI, monitor carefully especially in the beginning.
Slide 18-

Treatment of Depression All children with depression should have ongoing psychotherapy as this has been shown to reduce suicidal thoughts and behaviors. 2 If medications are indicated, begin with Fluoxetine It is the only FDA approved SSRI for depression in children 8 and up. If this does not work, consider switching to another SSRI 2. Citalopram, Escitalopram, Sertaline are all good options. Do not use Paroxetine. 14 If this still does not work, consider switching to venlafaxine. 12
Slide 19-

SSRI Treatment Choices for Depression
Slide 20-

Non-OCD Anxiety Disorders Treatment There are no FDA approved medications for children and adolescents for non-OCD anxiety disorders. Approximately 10-20% of children have an anxiety disorder such as GAD, Separation Anxiety Disorder, or Social Phobia. 3 Children and adolescents do best in combined therapy in which CBT and medications are prescribed.
Slide 21-

Non- OCD Anxiety Disorders While sertraline does not have FDA approval for treatment of anxiety disorders in children, there is good evidence for its efficacy. Medications should be dosed at rates done in clinical trials. 15 Typical dosages for sertraline based on CAMS study are 100-150 mg by week 15. Typical dosage for fluoxetine are based on TADS and TORDIA studies and show need to titrate up to 40 mg by week 12.
Slide 22-

OCD DON’T FORGET THE POWER OF PSYCHOTHERAPY!!! FDA approved medications for treatment of OCD Clomipramine > 10 y/o Fluvoxamine > 8 y/o Sertraline > 6 y/o Fluoxetine > 7 y/o Medication Augmentation: Clomipramine, Clonazepam, Neuroleptics, Add second SSRI, Lithium 16
Slide 23-

Pediatric Bipolar Disorder Controversial diagnosis Psychosocial interventions are necessary in addition to medications Approved Medications by FDA for manic and mixed states in ages 10-17: Lithium, Quetiapine, Risperidone, Aripiprazole. Olanzapine has been approved to age 13 and up. Also used but not officially approved: Carbamazepine, Divalproex in monotherapy and as augmentation to above agents, as well as Ziprasidone, Clozapine, and ECT (in adolescents). topiramate and oxcarbazepine only have negative studies in children under age 18, so DON”T USE THEM!!
Slide 24-

Oppositional Defiant Disorder Tx No official medications approved by FDA for treatment Best evidence is for psychotherapy (CBT, family) and psychosocial interventions Off-label use of stimulants (high comorbidity with ADHD), as well as mood stabilizers (Divalproex and Lithium) Atypical Antipsychotics used as well (Risperidone has some evidence) Bottom line is treat with psychotherapy and use medications for any comorbid psychiatric disorders.
Slide 25-

Autism Spectrum Pharmacotherapy NO medications approved for core symptoms Medications often used to treat related symptoms, such as depression, anxiety, and aggression Aggression: Risperidone is FDA approved Methylphenidate, Clonidine and naltrexone have preliminary data Insistence on Sameness: Lexapro has preliminary data, done at UIC Anxiety: often use SSRIs, at low doses Patients with autism are often very sensitive to adverse effects, even at low doses
Slide 26-

Thanks! Any Questions? Comments? Complaints? Contact Information: Email: avermani@psych.uic.edu Phone: 312.413.2985
Slide 27-

Citations 1.http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143565.htm 2. Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes. Am J Psychiatry. 2010 Jul;167(7):782-91. 3. Cognitive Behavioral Therapy, Sertraline, or a Combination in Childhood Anxiety N Engl J Med 2008; 359:2753-2766 4. Puig M: Body composition and growth. In Nutrition in Pediatrics, ed. 2, edited by WA Walker and JB Watkins. Hamilton, Ontario, BC Decker, 1996. 5. Polanczyk, G Epidemiology of ADHD across the lifespan. Curr Opinion Psych 20(386-92); 2007 6. Martin, A. Lewis’s Child and Adolescent psychiatry, a comprehensive textbook, Fourth Ed. 2007, 432 – 439. 7. The MTA cooperative Group, A 14 month randomized clinical trial of treatment strategies for attention deficit hyperactivity disorder. Arch of Gen Psychiatry, 1999; 56;1073-1086. 8. Faraone, Comparing the efficacy of stimulants for ADHD in children and adolescents using a meta-analysis. Eur Child and Adolescent Psychiatry (2010)19; 353-364
Slide 28-

Citations 9. Mental Health: A Report of the Surgeon General 1999; Chapter 3. 10. Gibbons, R. The Relationship between Antidepressant Rates and Rates of Early Adolescent Suicide. American J. Psychiatry 163:11, November 2006. 11. Bridge, J. Clinical Response and Risk for Reported Suicidal Ideation and Suicide Attempts in Pediatric Antidepressant Treatment. JAMA (2007) 297:15: 1683-96. 12. Miller M, Azrael D, Hepburn L, Hemenway D, Lippmann SJ. The association between changes in household firearm ownership and rates of suicide in the United States, 1981-2002. Injury Prevention 2006;12:178-182 13. Vitiello B, et al. (2007). Effectiveness of methylphenidate in the 10-month continuation phase of the preschoolers with ADHD treatment study (PATS). Journal of Child and Adolescent Psychopharmacology, 17(5): 593-603. 14. CHMP meeting on Paroxetine and other SSRIs. European Medicines Agency. 2004-12-09.
Slide 29-

Citations 15. John Walkup, Child and Adolescent Psychopharmacology: Integrating Current Data into Clinical Practice. January 21, 2012. 16. March J. Expert Consensus guidelines: treatment of obsessive compulsive disorder. J. Clinical Psychiatry. 1997; 58(1-72).